Final Results from Phase II Trial of Neoadjuvant Docetaxel and Capecitabine Given Sequentially or Concurrently for HER2-Negative Breast Cancers.

CONCLUSION: The combination of docetaxel and capecitabine has modest activity in the neoadjuvant setting. These results are consistent with other trials using this combination in the neoadjuvant setting.
PMID: 23332349 [PubMed - as supplied by publisher]

Source: Clinical Breast Cancer - January 15, 2013 Category: Cancer & Oncology Authors: Zelnak AB, Styblo TM, Rizzo M, Gabram SG, Wood WC, Harichand-Herdt S, Kim S, Liu Y, O'Regan RM, Georgia Center for Oncology Research and Education Tags: Clin Breast Cancer Source Type: research